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Abstract
Background. Atrial fibrillation (AF) remains one of the major causes of cardiovascular morbidity worldwide. Left 
atrial enlargement (LAE) is a common risk factor of AF. Left atrial enlargement is also connected with a higher 
prevalence of heart failure in AF patients. The aim of this study was to assess the prevalence of LAE in Polish patients 
with AF. 
Material and methods. Transthoracic echocardiography was performed in consecutive AF patients hospitalized in 
the Department of Heart Diseases. We assessed LAE using a two-dimensional method. Left atrial (LA) size was clas-
sified into the 4 categories: normal (LAE values < 39 mm in women and < 41 mm in men), mildly enlarged (39–42 
mm in women and 41–46 mm in men), moderately enlarged (43–46 mm in women and 47–51 mm in men), and 
severely enlarged (≥ 47 mm in women and ≥ 52 mm in men). 
Results. We analyzed 113 individuals with AF (mean age 77.2 ± 9.8 years; 37.2% men). Of these, 71 (62.8%) pa-
tients had LAE (age 77.6 ± 9.9 years; 36.6% men). LA was mildly enlarged (39–42 mm in women and 41–46 mm 
in men) in 20 (28.2%) patients, moderately enlarged (43–46 mm in women and 47–51 mm in men) was observed 
in 30 (42.3%), and severely enlarged (≥ 47 mm in women and ≥ 52 mm in men) in 21 (29.6%) patients. The 
incidence of heart failure was significantly higher in AF patients with LAE [39 (54.9%) compared to the patients 
without LAE — 12 (28.6%) p = 0.01]. 
Conclusions. In patients with AF, LAE was highly prevalent. Patients with AF and LAE have more often HF com-
pared to AF patients without LAE.
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Introduction
Atrial fibrillation (AF), the most common supraven-
tricular arrhythmia, is found in approximately 3% 
adults and its prevalence is still rising. Atrial fibrilla-
tion remains one of the major causes of stroke, heart 
failure (HF), sudden death, and cardiovascular mor-
bidity worldwide [1]. It occurs more often in patients 
with a left atrial enlargement (LEA) [2]. Left atrial 
(LA) size is a predictor of cardiovascular outcomes 
in the general population and HF patients [3]. As 
previously shown, LAE is also connected with higher 
thromboembolic risk in AF patients [4]. 
The aim of this study was to assess the prevalence 
of LAE in patients with nonvalvular AF.
Material and methods
The study was designed and conducted with the ac-
cordance of the Declaration of Helsinki and it was 
approved by the Regional Ethics Committee. We 
prospectively analyzed data on continuous hospital-
izations for AF in the Department of Heart Diseases, 
Medial Centre of Postgraduate Education, Warsaw. 
Inclusion criteria were age ≥ 18 years, primary diag-
nosis of AF, transthoracic echocardiographic evalua-
tion underwent during current hospitalization. We 
excluded patients with valvular AF, fatal condition 
with an estimated life expectancy of < 6 months, 
or those who did not give informed consent for the 
participation in the study. Medical history was taken 
in all patients on admission by a qualified physician. 
Data included information on thromboembolic and 
cardiovascular risk factors. The diagnosis of AF was 
made based on the rhythm documentation using 
a standard electrocardiogram (ECG) showing the 
typical pattern of AF, according to the current guide-
lines [2]. 
In all, transthoracic echocardiograms were per-
formed in the Department’s Echocardiography 
Laboratory using Philips Affiniti 70C Ultrasound 
Machines (Philips Healthcare, Andover, USA) by 
qualified echocardiographers. To avoid bias, mea-
surements were taken three times, then averaged. 
LA diameter was measured using two-dimensional 
(2D) echocardiography, from the posterior aortic 
wall to the posterior left atrial wall, in the parasternal 
long-axis view at the end-ventricular systole (i.e., 
just before the mitral valve opening). Left atrial en-
largement was classified into four categories: normal, 
mildly enlarged, moderately enlarged, and severely 
enlarged by the European Society of Cardiology 
guidelines [5]. Left atrial size was considered normal 
when LA was < 39 mm in women and < 41 mm in 
men, otherwise it was considered enlarged. The mild 
enlargement was defined as LAE values 39–42 mm 
in women and 41–46 mm in men, moderate enlarge-
ment for 43–46 mm in women and 47–51 mm in 
men, and severe enlargement for ≥ 47 mm in women 
and ≥ 52 mm in men. Left ventricular ejection frac-
tion (LVEF) was calculated using the biplane method 
of discs (modified Simpson’s rule) [5].
All data are presented as mean ± standard devia-
tion (SD) for parametric variables and as percentages 
for categorical variables. Continuous variables were 
checked for the normal distribution assumption us-
ing the Kolmogorov-Smirnov statistics. Differences 
between the prespecified patient groups were evalu-
ated using the Kolmogorov-Smirnov test or ANOVA 
with Tukey’s post hoc test as appropriate. Categorical 
variables were tested by Pearson’s c2 test and Fisher’s 
exact test. A p-value < 0.05 was considered statisti-
cally significant. All statistical studies were carried 
out using Statistical Package for Social Sciences soft-
ware (SPSS 21.0 for macOS, SPSS Inc., Chicago, 
IL, USA).
Results
The study population consisted of 113 individuals 
with AF (mean age 77.2 ± 9.8 years; 37.2% men). In 
this group, the mean value of LA diameter was 42.2 
± 8.2 millimeters. Hypertension was present in 97 
(85.4 %) patients, diabetes mellitus in 39 (34.5 %) 
patients, chronic coronary syndromes in 43 (38%) 
patients, stroke or transient ischemic attack in 22 
(19.5%) patients, HF in 51 (45.1%) patients and 
chronic obstructive pulmonary disease in 15 (13.3%) 
patients. Baseline characteristics of study patients are 
shown in Table I. 
In the group of AF patients, we identified 71 
(62.8%) patients with LAE (age 77.6 ± 9.9 years; 
36.6% men) and 42 (37.2%) patients without LAE 
(76.6 ± 9.7 years; 33.3% men). There was no sig-
nificant difference in the incidence of hypertension, 
diabetes mellitus, chronic coronary syndromes, 
chronic kidney disease, stroke or transient ischemic 
attack, as well as chronic obstructive pulmonary 
disease in these two groups. The incidence of HF 
was significantly higher in AF patients with LAE 
[39 (54.9%) compared to the patients without LAE 
— 12 (28.6%), p = 0.01]. The characteristics of the 
study population according to the LAE status are 
shown in Table II.
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Discussion
The assessment of LA size is crucial to determine 
the LA function. During the cardiac cycle, LA size 
is changing and in clinical practice, the maximum 
LA size (at the end of the left ventricle systole) is 
the most often used parameter. The measurement of 
anteroposterior LA linear dimension by 2D echocar-
diography in the parasternal long-axis view remains 
the most common echocardiographic method, be-
cause of its simplicity and reproducible.  
Left atrial enlargement reflects structural remod-
eling associated with pathophysiologic processes in 
different cardiovascular diseases (CVD). Condi-
tions such as hypertension, HF, diabetes mellitus, 
and obesity are the most common risk factors of 
LA remodeling. In hypertensive patients, associated 
hypertrophy and diastolic dysfunction lead to LEA. 
Left atrial enlargement is not the only consequence 
of high blood pressure, but also a predictor of out-
come in hypertension [6]. Hypertension increases 
the risk of AF [7]. In our population of AF patients, 
hypertension was observed in most patients (85.4%), 
without significant differences between patients with 
and without LAE. 
Previous studies have shown that LA size has 
been associated with adverse cardiovascular out-
comes. Left atrial enlargement has been described 
as a predictor of AF, stroke, congestive HF, and 
cardiovascular death. In our study, LAE was highly 
prevalent in nonvalvular AF patients (almost 62.8% 
of patients). Echocardiographically determined LA 
size is one of the stroke risk factors overlooked by 
the scores used for thromboembolic risk stratifica-
tion. LA size may be an additional predictor useful 
in the assessment of thromboembolic events in AF 
patients. As we presented in our previous study, 
LAE has been associated with higher thromboem-
bolic risk assessed by CHADS2 and CHA2DS2-
VASc scores [4]. 
The clinical implications of LAE  can be left 
ventricular dysfunction, which occurs in 20–30% 
AF patients [2]. Left atrial enlargement has been 
shown as a marker of poor prognosis in HF patients. 
Previous studies have demonstrated that LA size is 
a powerful predictor of outcome among HF patients 
with predominantly impaired systolic function and 
provides additional prognostic information beyond 
left ventricular systolic and diastolic function. (3) 
The results of our study showed, that the prevalence 
of HF was significantly higher in AF patients with 
LAE compared to AF patients without LAE. What 
is important, the mean value of LVEF did not differ 
significantly between these two groups.





Age (yrs) 77.2 ± 9.8
Male [n (%)] 42 (37.2)
BMI [kg/m2] 29.1 ± 4.9
Obesity [n (%)] 33 (29.2)
SBP [mm Hg] 133.4 ± 20.6
DBP [mm Hg] 80 ± 13.6
IVSd [mm] 13.1 ± 2.6
LAE [n (%)] 71 (62.8)
Lad [mm] 42.2 ± 8.2
Hypertension [n (%)] 97 (85.4%)
Diabetes mellitus [n (%)] 39 (34.5%)
Chronic coronary syndromes [n (%)] 43 (38%) 
Stroke, TIA [n (%)] 22 (19.5%)
Heart failure [n (%)] 51 (45.1%)
COPD [n (%)] 15 (13.3%)
BMI — body mass index; IVSd — intraventricular septum diameter; SBP — systolic blood pressure; 
DBP — diastolic blood pressure; LAd — left atrium diameter; TIA — transient ischemic attack;  
COPD — chronic obstructive pulmonary disease
Table II. Baseline characteristics of the study population accor-




(n = 42) p-value
Age (yrs) 77.6 ± 9.9 76.6 ± 9.7 > 0.05
Male [n (%)] 26 (36.6%) 14 (33.3) > 0.05
BMI [kg/m2] 29.7 ± 5.3 28.1 ± 4.1 > 0.05
Obesity [n (%)] 24 (33.8) 9 (21.4) > 0.05
SBP [mm Hg] 134 ± 21.8 132.4 ± 18.7 > 0.05
DBP [mm Hg] 81.4 ± 14.1 77.1 ± 12.7 > 0.05
IVSd [mm] 13.1 ± 2.6 12.4 ± 2 > 0.05
LVEF (%) 53.5 ± 13.8 57.1 ± 10.1 > 0.05
Hypertension [n (%)] 60 (84.5) 37 (88.1) > 0.05
Diabetes mellitus 
[n (%)] 26 (36.6) 13 (31) > 0.05
Chronic kidney 
disease [n (%)] 25 (35.2) 11 (26.2) > 0.05
Chronic coronary 
syndromes [n (%)] 28 (39.4) 15 (35.7) > 0.05
Stroke, TIA [n (%)] 11 (15.5) 11 (26.2) > 0.05
Heart failure [n (%)] 39 (54.9) 12 (28.6) = 0.01
COPD [n (%)] 10 (14.1) 5 (11.9) > 0.05
AF — atrial fibrillation; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic 
blood pressure; LAE — left atrial enlargement; IVSd — intraventricular septum diameter; LVEF — left 
ventricular ejection fraction; TIA — transient ischemic attack; COPD — chronic obstructive pulmonary 
disease
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Limitations in this study  were a small popula-
tion of the study, one center study and the lack of 
comparison of different methods used for assessing 
LA size. 
Conclusions
Left atrial enlargement is highly present in the Polish 
population of AF patients and can carry important 
clinical and prognostic implications. Patients with 
AF and LAE are at higher risk of HF. Left atrial size 
can also have prognostic value. Further studies suf-
ficiently powered to assess this issue may be needed.
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